Spinal Stabilization Technologies enrolled the first U.S. patient in its Investigational Device Exemption (IDE) clinical trial for the PerQdisc Nucleus Replacement Device.
The IDE trial will assess the PerQdisc’s ability to replace the nucleus pulposus of a single lumbar disc (L1-L5) with the intent to preserve motion and alleviate pain. Currently, patients with painful lumbar DDD face limited surgical options, with many resorting to spinal fusion, which restricts motion and places increased stresses on adjacent spinal levels. SST’s PerQdisc is a breakthrough alternative that avoids fusion and leaves the surrounding anatomy intact.
To support the trial and accelerate its path toward regulatory approval, SST recently raised $17 million in funding from existing and new investors. This investment will advance the IDE trial and further clinical development initiatives.
“The reduction in pain and overall clinical outcomes observed with PerQdisc during the feasibility trials (over 40 patients treated) have been exceptional,” stated Dr. Pierce Nunley, Principal Investigator and Medical Director of the Spine Institute of Louisiana. “The procedure was notably straightforward, and the recovery period is anticipated to be brief. This technology holds the potential to revolutionize the treatment of patients suffering from discogenic low back pain, providing a straightforward, safe, and minimally invasive option that reduces pain and maintains mobility while restoring functionality.”
Spinal Stabilization Technologies enrolled the first U.S. patient in its Investigational Device Exemption (IDE) clinical trial for the PerQdisc Nucleus Replacement Device.
The IDE trial will assess the PerQdisc's ability to replace the nucleus pulposus of a single lumbar disc (L1-L5) with the intent to preserve motion and alleviate pain....
Spinal Stabilization Technologies enrolled the first U.S. patient in its Investigational Device Exemption (IDE) clinical trial for the PerQdisc Nucleus Replacement Device.
The IDE trial will assess the PerQdisc’s ability to replace the nucleus pulposus of a single lumbar disc (L1-L5) with the intent to preserve motion and alleviate pain. Currently, patients with painful lumbar DDD face limited surgical options, with many resorting to spinal fusion, which restricts motion and places increased stresses on adjacent spinal levels. SST’s PerQdisc is a breakthrough alternative that avoids fusion and leaves the surrounding anatomy intact.
To support the trial and accelerate its path toward regulatory approval, SST recently raised $17 million in funding from existing and new investors. This investment will advance the IDE trial and further clinical development initiatives.
“The reduction in pain and overall clinical outcomes observed with PerQdisc during the feasibility trials (over 40 patients treated) have been exceptional,” stated Dr. Pierce Nunley, Principal Investigator and Medical Director of the Spine Institute of Louisiana. “The procedure was notably straightforward, and the recovery period is anticipated to be brief. This technology holds the potential to revolutionize the treatment of patients suffering from discogenic low back pain, providing a straightforward, safe, and minimally invasive option that reduces pain and maintains mobility while restoring functionality.”
Copy to clipboard 
